Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

BACKGROUND: The Intergroup Exemestane Study (IES) (ISRCTN11883920) demonstrated improved survival for postmenopausal women with ER-positive/unknown primary breast cancer who switched to exemestane after 2–3 years tamoxifen, compared with those continuing on tamoxifen to complete 5 years therapy. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallowfield, L J, Kilburn, L S, Langridge, C, Snowdon, C F, Bliss, J M, Coombes, R C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304414/
https://www.ncbi.nlm.nih.gov/pubmed/22353807
http://dx.doi.org/10.1038/bjc.2012.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304414/
https://www.ncbi.nlm.nih.gov/pubmed/22353807
http://dx.doi.org/10.1038/bjc.2012.43

Ejemplares similares